Clinical Trials Logo

Tobacco Use Disorder clinical trials

View clinical trials related to Tobacco Use Disorder.

Filter by:

NCT ID: NCT00006170 Completed - Clinical trials for Tobacco Use Disorder

Bupropion and Weight Control for Smoking Cessation - 1

Start date: September 2000
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether the addition of bupropion (Zyban) to cognitive behavioral therapy (CBT) will enhance longer-term tobacco abstinence in women.

NCT ID: NCT00006151 Completed - Clinical trials for Tobacco Use Disorder

Combining a Smoke Ending Aid With Behavioral Treatment - 1

Start date: May 1999
Phase: N/A
Study type: Interventional

The purpose of this study is to combine a smoke ending aid with behavioral treatment.

NCT ID: NCT00002520 Completed - Breast Cancer Clinical Trials

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Start date: December 7, 1990
Phase: N/A
Study type: Interventional

RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking. PURPOSE: Randomized clinical trial to compare the effectiveness of a physician-initiated stop-smoking program with the usual care for patients receiving treatment for early-stage cancer.

NCT ID: NCT00000350 Active, not recruiting - Clinical trials for Tobacco Use Disorder

Effects of Stimulant Dependence on Human Striatal Dopamine System - 15

Start date: March 1999
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether DAT availability, assessed by WIN binding, in the striatum is altered in cocaine or methamphetamine dependence. To determine whether DA synthesis capacity, assessed by FDOPA uptake, in the striatum is altered in Coc or Meth dependence. To determine whether the PET tracers, WIN or FDOPA, will differentiate Meth induced alterations from those induced by Coc use. To determine whether the PET characterization of striatal alterations observed at 3-5 days since last drug use persists at least 3 months after last drug use.

NCT ID: NCT00000297 Completed - Clinical trials for Tobacco Use Disorder

Effects of Labetalol on Nicotine Administration in Humans - 14

Start date: October 1998
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine

NCT ID: NCT00000296 Completed - Clinical trials for Tobacco Use Disorder

Role of Metabolites in Nicotine Dependence (4) - 13

Start date: November 1997
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.

NCT ID: NCT00000295 Completed - Clinical trials for Tobacco Use Disorder

Progesterone Treatment in Female Smokers - 12

Start date: April 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate progesterone effects in female smokers

NCT ID: NCT00000289 Completed - Clinical trials for Tobacco Use Disorder

Role of Metabolites in Nicotine Dependence (3) - 6

Start date: May 1998
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.

NCT ID: NCT00000288 Completed - Clinical trials for Tobacco Use Disorder

Role of Metabolites in Nicotine Dependence (2) - 5

Start date: December 1995
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of varying doses of cotinine on cigarette self-administration.

NCT ID: NCT00000284 Completed - Clinical trials for Tobacco Use Disorder

Role of Metabolites in Nicotine Dependence (1) - 1

Start date: February 1995
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.